Rivastigmine Market Analysis By Disease Indication (Alzheimer Disease and Parkinson’s Disease), by Formulation ( Capsules and Transdermal Patches), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) & Forecast 2024-2035
- PUBLISHED ON
- 24/03/2023
- NO OF PAGES
- 275
- CATEGORY
- Healthcare & Life Sciences
Rivastigmine is a medication used to treat mild to moderate dementia associated with Alzheimer's and Parkinson's disease. It belongs to the class of cholinesterase inhibitors, which work by increasing the levels of a neurotransmitter called acetylcholine in the brain. Rivastigmine is available in various forms, including oral capsules, transdermal patches, and oral solutions.
The global rivastigmine market is driven by the increasing prevalence of Alzheimer's and Parkinson's disease, which are the primary indications for the use of this medication. According to the Alzheimer's Association, an estimated 6.2 million Americans aged 65 and older are living with Alzheimer's disease, and this number is projected to reach 12.7 million by 2050. Similarly, Parkinson's disease affects around 10 million people worldwide.
The market for rivastigmine is also driven by the increasing awareness about the benefits of early diagnosis and treatment of these diseases, which has led to a greater demand for medications like rivastigmine that can slow down the progression of the disease and improve the quality of life of patients.
The market for rivastigmine is highly competitive, with several established players and new entrants competing for market share. Some of the key players in the market include Novartis International AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., and Sun Pharmaceutical Industries Ltd. These companies are investing in research and development activities to develop new and innovative formulations of rivastigmine, as well as in marketing and promotional activities to increase awareness about the condition and the available treatments.
Overall, the global rivastigmine market is expected to witness significant growth in the coming years, driven by factors such as increasing prevalence of Alzheimer's and Parkinson's disease, increasing awareness about the benefits of early diagnosis and treatment, and the development of new and innovative formulations of rivastigmine.
Segment Overview
Rivastigmine is a medication used to treat symptoms of mild to moderate Alzheimer's disease and Parkinson's disease dementia. As such, the market segment for rivastigmine would be the pharmaceutical market for treatments for Alzheimer's and Parkinson's diseases. This market segment includes healthcare providers, hospitals, clinics, pharmacies, and patients or their caregivers who are seeking treatments for these conditions.
The market segment for rivastigmine may also include research institutions, as scientists and medical professionals may be interested in studying the medication's effectiveness and potential side effects, as well as exploring new applications for the drug. Additionally, the market segment may extend to insurance companies and government healthcare agencies, who may cover or subsidize the cost of the medication for eligible patients.
Geographical Overview
Rivastigmine is a medication used to treat symptoms of Alzheimer's disease and Parkinson's disease dementia. It is available under different brand names, including Exelon, Prometax, and Rivadem.
The market geography of rivastigmine is global, with the drug being sold and prescribed in many countries around the world. The largest markets for rivastigmine are in North America, Europe, and Asia.
In North America, the United States is the largest market for rivastigmine, with Canada also being a significant market. In Europe, the largest markets for rivastigmine are the United Kingdom, Germany, France, and Italy.
In Asia, Japan is a significant market for rivastigmine due to its aging population and high incidence of Alzheimer's disease. Other Asian countries, such as China and India, also have growing markets for rivastigmine due to increasing awareness of Alzheimer's disease and related dementias.
Overall, the global market for rivastigmine is expected to continue to grow in the coming years due to an aging population and increasing incidence of Alzheimer's disease and Parkinson's disease dementia.
COVID Impact
The COVID-19 pandemic has had an impact on the rivastigmine market in various ways. On the one hand, the demand for Alzheimer's disease medications, including rivastigmine, has increased due to the pandemic's impact on mental health. On the other hand, the pandemic has disrupted supply chains, manufacturing, and distribution of medications worldwide, which has affected the availability of rivastigmine in some regions.
One of the main impacts of the pandemic on the rivastigmine market has been the increased demand for Alzheimer's disease medications. The pandemic has caused stress, anxiety, and social isolation, which can exacerbate symptoms of dementia. As a result, there has been an increased demand for Alzheimer's disease medications, including rivastigmine, to help manage these symptoms.
However, the pandemic has also disrupted supply chains and manufacturing of medications worldwide. This has resulted in shortages of some medications, including rivastigmine, in some regions. Additionally, some patients may have experienced difficulties accessing healthcare facilities and obtaining their medications due to lockdowns and other COVID-19 related restrictions.
Overall, while the pandemic has increased demand for rivastigmine, it has also presented challenges in terms of supply and distribution. The extent of the impact has varied by region and is likely to continue evolving as the pandemic situation develops.
Competitive Analysis
The rivastigmine market is competitive, with several companies manufacturing and marketing the drug under different brand names. The key players in the rivastigmine market include:
• Novartis: Novartis markets rivastigmine under the brand name Exelon. Exelon is available in several formulations, including oral capsules, oral solution, and transdermal patches.
• Pfizer: Pfizer markets rivastigmine under the brand name Prometax. Prometax is available in oral capsules and oral solution formulations.
• Teva: Teva markets rivastigmine under the brand name Rivastigmine Teva. Rivastigmine Teva is available in oral capsules and oral solution formulations.
• Mylan: Mylan markets rivastigmine under the brand name Rivastigmine Mylan. Rivastigmine Mylan is available in oral capsules and oral solution formulations.
• Sun Pharma: Sun Pharma markets rivastigmine under the brand name Rivadem. Rivadem is available in oral capsules and oral solution formulations.
Other companies, including Sandoz, Zydus Cadila, and Cipla, also manufacture and market generic versions of rivastigmine.
In terms of market share, Novartis is currently the largest player in the rivastigmine market, followed by Pfizer and Teva. However, the market share of each company can vary by region and product formulation. The competition in the market is expected to remain strong due to the increasing demand for Alzheimer's disease medications and the entry of new players into the market.
Historic Year: 2016-2022
Forecast: 2024-2035
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached Straits Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2028.
}})
Select a license type that suits your business needs
US $3950
Only Three Thousand Nine Hundred Fifty US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $4950
Only Four Thousand Nine Hundred Fifty US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $5950
Only Five Thousand Nine Hundred Fifty US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI